- Home
- CORT
as 04-18-2025 1:34pm EST
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 7.1B | IPO Year: | N/A |
| Target Price: | $143.25 | AVG Volume (30 days): | 2.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.23 | EPS Growth: | 30.85 |
| 52 Week Low/High: | $20.84 - $117.33 | Next Earning Date: | 04-30-2025 |
| Revenue: | $675,040,000 | Revenue Growth: | 39.94% |
| Revenue Growth (this year): | 36.81% | Revenue Growth (next year): | 32.00% |
Stock Insider Trading Activity of Corcept Therapeutics Incorporated (CORT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Guyer William | CORT | Chief Development Officer | Apr 1 '25 | Sell | $114.51 | 678 | $77,639.00 | 5,487 | |
| Lyon Joseph Douglas | CORT | See Remarks | Mar 31 '25 | Sell | $104.65 | 200,650 | $20,167,953.55 | 47,001 | |
| Maduck Sean | CORT | See Remarks | Mar 31 '25 | Sell | $104.60 | 100,590 | $10,121,593.92 | 91,212 | |
| BELANOFF JOSEPH K | CORT | Chief Executive Officer | Mar 31 '25 | Sell | $104.72 | 35,452 | $3,365,009.94 | 2,982,335 | |
| Lyon Joseph Douglas | CORT | See Remarks | Mar 24 '25 | Sell | $60.58 | 421 | $25,504.18 | 47,001 | |
| Maduck Sean | CORT | See Remarks | Mar 24 '25 | Sell | $60.58 | 1,697 | $102,804.26 | 91,212 | |
| BELANOFF JOSEPH K | CORT | Chief Executive Officer | Mar 24 '25 | Sell | $60.83 | 1,974 | $120,084.14 | 2,982,335 | |
| Swisher Daniel N JR | CORT | Director | Mar 10 '25 | Sell | $53.60 | 2,200 | $117,920.00 | 0 | |
| Lyon Joseph Douglas | CORT | See Remarks | Feb 28 '25 | Sell | $60.69 | 4,579 | $277,901.80 | 47,001 | |
| Maduck Sean | CORT | See Remarks | Feb 28 '25 | Sell | $60.69 | 18,303 | $1,110,818.22 | 91,212 |
Latest Corcept Therapeutics Incorporated News
CORT Breaking Stock News: Dive into CORT Ticker-Specific Updates for Smart Investing
Argus Research
3 days ago
CORT: Lowering target price to $76.00
Simply Wall St.
9 days ago
Corcept Therapeutics (NasdaqCM:CORT) Rises 36% in Last Quarter
Argus Research
10 days ago
CORT: Lowering target price to $78.00
Business Wire
12 days ago
Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer
MT Newswires
16 days ago
Corcept Therapeutics Insider Sold Shares Worth $10,121,594, According to a Recent SEC Filing
Zacks
16 days ago
Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More
Zacks
17 days ago
Does Corcept (CORT) Have the Potential to Rally 28.63% as Wall Street Analysts Expect?
Argus Research
17 days ago
CORT: Raising target price to $120.00
Compare CORT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CORT Corcept Therapeutics Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.